Oxycodone

Nazia M. Sadiq, Travis J. Dice, Therese Mead, Nazia M. Sadiq, Travis J. Dice, Therese Mead

Excerpt

Oxycodone is a potent semisynthetic opioid with agonistic properties on mu-, kappa-, and delta-type opioid receptors. This drug is beneficial when used judiciously for pain management, yet it carries the risk of inducing physical dependence and addiction. The immediate-release formulation of oxycodone is approved by the US Food and Drug Administration (FDA) for managing acute or chronic moderate-to-severe pain when opioid medication is considered suitable and alternative pain management strategies are inadequate. The extended-release formulation is FDA-approved for managing severe pain that necessitates continuous, long-term opioid treatment when no alternative options are available to address the pain.

Conflict of interest statement

Disclosure: Nazia Sadiq declares no relevant financial relationships with ineligible companies.

Disclosure: Travis Dice declares no relevant financial relationships with ineligible companies.

Disclosure: Therese Mead declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

References

    1. Torabi R, Bourn L, Mundinger GS, Saeg F, Patterson C, Gimenez A, Wisecarver I, St Hilaire H, Stalder M, Tessler O. American Society of Plastic Surgeons Member Post-Operative Opioid Prescribing Patterns. Plast Reconstr Surg Glob Open. 2019 Mar;7(3):e2125.
    1. Kalso E. Oxycodone. J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56.
    1. Thigpen JC, Odle BL, Harirforoosh S. Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):591-609.
    1. Roxybond--an abuse-deterrent formulation of short-acting oxycodone. Med Lett Drugs Ther. 2018 Sep 10;60(1555):145-146.
    1. Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92.
    1. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S3-13.
    1. Balyan R, Mecoli M, Venkatasubramanian R, Chidambaran V, Kamos N, Clay S, Moore DL, Mavi J, Glover CD, Szmuk P, Vinks A, Sadhasivam S. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics. 2017 Mar;18(4):337-348.
    1. Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18(4):17-30.
    1. Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone. Clin Pharmacokinet. 2019 Jun;58(6):705-725.
    1. Drugs and Lactation Database (LactMed®) [Internet] National Institute of Child Health and Human Development; Bethesda (MD): 2024. Apr 15, Oxycodone.
    1. Sachs HC, Committee On Drugs The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809.
    1. van Dorp E, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32.
    1. Remillard D, Kaye AD, McAnally H. Oxycodone's Unparalleled Addictive Potential: Is it Time for a Moratorium? Curr Pain Headache Rep. 2019 Feb 28;23(2):15.
    1. Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019 Apr;20(5):511-522.
    1. Kiyatkin EA. Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. Neuropharmacology. 2019 Jun;151:219-226.
    1. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol. 2012 Jan;68(1):55-64.
    1. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18.
    1. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol. 2011 Jan;67(1):63-71.
    1. Dolinak D. Opioid Toxicity. Acad Forensic Pathol. 2017 Mar;7(1):19-35.
    1. Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018 Aug;92(8):2457-2473.
    1. Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, Cornett EM, Kaye AM, Kaye AD. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol Res. 2022;10(4):39576.
    1. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Substance Abuse and Mental Health Services Administration (US); Rockville (MD): 2004.
    1. Egan TD, Brock-Utne JG. Asystole after anesthesia induction with a fentanyl, propofol, and succinylcholine sequence. Anesth Analg. 1991 Dec;73(6):818-20.
    1. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007 May 17;356(20):2064-72.
    1. Kokko H, Hall PD, Afrin LB. Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy. 2002 Sep;22(9):1188-92.
    1. Clark K, Lam LT, Agar M, Chye R, Currow DC. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med. 2010 Jun;24(4):410-8.
    1. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-88.
    1. Nelson LS, Loh M, Perrone J. Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies. J Med Toxicol. 2014 Jun;10(2):165-72.
    1. Esposito DB, Huybrechts KF, Werler MM, Straub L, Hernández-Díaz S, Mogun H, Bateman BT. Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns. JAMA Netw Open. 2022 Aug 01;5(8):e2228588.
    1. Rauck RL. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. Pain Pract. 2019 Apr;19(4):443-454.
    1. Freedman-Weiss MR, Chiu AS, Solomon DG, Christison-Lagay ER, Ozgediz DE, Cowles RA, Caty MG, Stitelman DH. Opioid Prescribing Habits of General Versus Pediatric Surgeons After Uncomplicated Laparoscopic Appendectomy. J Surg Res. 2019 Mar;235:404-409.
    1. Concheiro M, Chesser R, Pardi J, Cooper G. Postmortem Toxicology of New Synthetic Opioids. Front Pharmacol. 2018;9:1210.
    1. Henry SG, Stewart SL, Murphy E, Tseregounis IE, Crawford AJ, Shev AB, Gasper JJ, Tancredi DJ, Cerdá M, Marshall BDL, Wintemute GJ. Using Prescription Drug Monitoring Program Data to Assess Likelihood of Incident Long-Term Opioid Use: a Statewide Cohort Study. J Gen Intern Med. 2021 Dec;36(12):3672-3679.
    1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): 2020. Nov 24, Oxycodone.
    1. Tanne JH. FDA approves over the counter sale of naloxone to reverse drug overdoses. BMJ. 2023 Mar 30;380:749.
    1. Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols SD. A New Tool to Tackle the Opioid Epidemic: Description, Utility, and Results from the Maine Diversion Alert Program. Pharmacotherapy. 2017 Jul;37(7):791-798.

Source: PubMed

Upcoming Clinical Trials

Subscribe